CB304
Providing a new paradigm of patient-specifictreatment using proprietary cancer diagnosis markers.
CB304 is a project to develop a cancer diagnostic kit using a new cancer diagnosis marker. CB304 is a new cancer diagnosis marker discovered exclusively by CentricsBio. It is expressed in cancer cells and exists in the blood. The CB304 project develops a rapid diagnostic kit and a diagnostic ELISA kit for measuring CB304 in the blood.
We develop a diagnostic ELISA kit and a rapid diagnostic kit for quantification to measure cancer by measuring the concentration of CB304 in the blood. This diagnostic kit that has the degree of sensitivity and specificity of the diagnosis of more than 95% and sets a new standard for cancer diagnosis. Quantitative determination of CB304 in the blood can also reduce the side effects of chemotherapy by injecting the appropriate amount of cancer treatment into the patient. Also, the diagnostic kit has the advantage that you can easily check the diagnosis of cancer within 20 minutes in the field.
The research and development of CB304 are divided into three categories. The first step is to collect reference materials and clinical specimens (positive and negative) in cooperation with several research institutes at home and abroad. The second step is to develop a recombinant protein and monoclonal antibody suitable for the development of high sensitivities of diagnostic kits, optimize marker conjugation and enhance the reagent composition. The third step is to prepare a diagnostic kit prototype and conduct analytical and clinical performance evaluation using standard materials and clinical samples.
The commercialization of the CB304 diagnostic kit can provide more opportunities for humans to diagnose cancer early. This provides a method for medical practitioners (doctors, nurses) to measure CB304 to diagnose cancer, monitor the measurements of CB304 to give patients the right amount of treatment, and determine whether the disease is cured. The cancer diagnosis kit developed by our company may be emerging as a new conceptual paradigm that shifts from a conventional treatment-oriented medical system to a patient-specific diagnosis and a prognosis-oriented medical system. By raising the credibility of preventing and treating diseases, we hope to contribute to improving the healthy life and quality of humankind and strengthening the national competitiveness of the bio industry.